Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients With HER2⁺ Metastatic Breast Cancer

Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients With HER2+ Metastatic Breast Cancer Mohammad Jahanzeb, Joanne E. Mortimer, Furhan Yunas, David H. Irwin, James Speyer, Alan J. Koletsky, Paula Klein, Tariq Sabir, Lori Kronish Oncologist 2002; 7: 410-417 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Summarize the epidemiology and natural history of HER2+ breast cancer. Differentiate the two primary methods for measuring HER2 in breast cancer patients. Appreciate the rationale for investigating vinorelbine in combination with trastuzumab. Discuss the relative efficacy and safety of trastuzumab and vinorelbine in HER2+ breast cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Oct. 25, 2002 Most Recent Review: June 10, 2005* Most Recent Update: Oct. 25, 2002 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.